Patents Assigned to Medarex
  • Angiopoietin-2 specific binding agents
    Patent number: 7521053
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: April 21, 2009
    Assignees: Amgen Inc., Medarex, Inc.
    Inventor: Jonathan Daniel Oliner
  • Cytotoxic compounds and conjugates
    Patent number: 7517903
    Abstract: The present disclosure provides drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-cleavable substrate conjugates, and to methods of treatment using them.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: April 14, 2009
    Assignee: Medarex, Inc.
    Inventors: Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Zhi-Hong Li, Bilal Sufi
  • Peptidyl prodrugs and linkers and stabilizers useful therefor
    Patent number: 7507420
    Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: March 24, 2009
    Assignee: Medarex, Inc.
    Inventors: Howard P. Ng, Danny P. C. McGee, Guoxian Wu, Jimmie Moore, Zhi-Hong Li, Sanjeev Gangwar, Oliver L. Saunders, Irina Astafieva
  • Surrogate Therapeutic Endpoint For Anti-CTLA-4 Based Immunotherapy Of Disease
    Publication number: 20090074752
    Abstract: The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
    Type: Application
    Filed: October 27, 2008
    Publication date: March 19, 2009
    Applicant: Medarex, Inc.
    Inventors: Israel Lowy, Geoffrey M. Nichol
  • Prodrugs activated by plasmin and their use in cancer chemotherapy
    Publication number: 20090076176
    Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.
    Type: Application
    Filed: June 11, 2008
    Publication date: March 19, 2009
    Applicant: MEDAREX, INC.
    Inventors: Andre Trouet, Vincent Dubois, Alexandre Passioukov
  • Transgenic non-human animals for producing chimeric antibodies
    Patent number: 7501552
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: March 10, 2009
    Assignee: Medarex, Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Monoclonal Antibodies Against Prostate Specific Membrane Antigen (PSMA) Lacking in Fucosyl Residues
    Publication number: 20090060908
    Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
    Type: Application
    Filed: February 17, 2006
    Publication date: March 5, 2009
    Applicant: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, David B. Passmore, Jenny Albanese, Lei Zhu
  • Disulfide prodrugs and linkers and stabilizers useful therefor
    Patent number: 7498302
    Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
    Type: Grant
    Filed: May 20, 2005
    Date of Patent: March 3, 2009
    Assignee: Medarex, Inc.
    Inventors: Howard P. Ng, Zhi-Hong Li, Danny P. C. McGee, Oliver L. Saunders, Guoxian Wu, David J. King, Valeri Martichonok, Sharon Elaine Boyd, Thomas J. Lobl
  • HUMAN MONOCLONAL ANTIBODIES TO BE PROGRAMMED DEATH LIGAND 1 (PD-L1)
    Publication number: 20090055944
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
    Type: Application
    Filed: June 30, 2006
    Publication date: February 26, 2009
    Applicant: MEDAREX, INC.
    Inventors: Alan J. Korman, Mark J. Selby, Changyu Wang, Mohan Srinivasan, David B. Passmore, Haichun Huang, Haibin Chen
  • Monoclonal antibody specific for the extracellular domain of prostate specific membrane antigen
    Patent number: 7476513
    Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM?) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM? allows the use of an immunoenzymatic assay for their detection.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: January 13, 2009
    Assignee: Medarex, Inc.
    Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William T. Tino
  • Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
    Patent number: 7465446
    Abstract: The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: December 16, 2008
    Assignee: Medarex, Inc.
    Inventors: Israel Lowy, Geoffrey M. Nichol
  • Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
    Patent number: 7465451
    Abstract: The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use for the diagnosis.
    Type: Grant
    Filed: December 27, 2006
    Date of Patent: December 16, 2008
    Assignee: Medarex, Inc.
    Inventors: Patrick Benoit, Francois Meyer, Deborah Maguire, Ivan Plavec, Michael Gerard Tovey
  • Methods for characterizing glycosylation sites
    Publication number: 20080299678
    Abstract: The present invention provides methods for isolating and characterizing the glycosylation sites of a glycoprotein, such as a glycosylated antibody. In particular, the methods employ affinity capture, liquid chromatography, and mass spectrometry to determine, for example, the location of the glycopeptide, the heterogeneity of the glycan attached to the glycopeptide, the mass of the glycopeptide, and/or the peptide sequence.
    Type: Application
    Filed: May 16, 2008
    Publication date: December 4, 2008
    Applicant: MEDAREX, INC.
    Inventors: Zhigang Wu, Mohan Srinivasan
  • Cytotoxic Compounds and Conjugates
    Publication number: 20080293800
    Abstract: The present disclosure provides cytoxic compounds useful as drugs or prodrugs and to drug-cleavable substrate conjugates where the drug and cleavable substrate are optionally linked through a self-immolative linker.
    Type: Application
    Filed: November 9, 2006
    Publication date: November 27, 2008
    Applicant: MEDAREX, INC.
    Inventors: Sanjeev Gangwar, Bilal Sufi
  • Human monoclonal antibodies against protective antigen
    Patent number: 7456264
    Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: November 25, 2008
    Assignee: Medarex, Inc.
    Inventors: Tibor Keler, Israel Lowy, Laura A. Vitale, Diann Blanset, Mohan Srinivasan
  • Methods of treatment using CTLA-4 antibodies
    Patent number: 7452535
    Abstract: The present invention provides method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: November 18, 2008
    Assignee: Medarex, Inc.
    Inventors: Thomas Andrew Davis, Tibor P. Keler, Robert F. Graziano, Alan J. Korman
  • Methods and Compounds For Preparing Cc-1065 Analogs
    Publication number: 20080281102
    Abstract: A method of forming a CBI CC-1065 analog utilizes NH2 as a starting material, where R3 is H or alkyl and R6 is H, substituted or unsubstituted lower alkyl, cyano, or alkoxy. Intermediates (I) are used and are claimed.
    Type: Application
    Filed: October 18, 2006
    Publication date: November 13, 2008
    Applicant: MEDAREX, INC.
    Inventors: Sanjeev Gangwar, Qian Zhang
  • Antibody-Drug Conjugates and Methods of Use
    Publication number: 20080279868
    Abstract: The present disclosure provides antibody-drug conjugates that are potent cytotoxins, wherein the drug is linked to the antibody through a linker. The disclosure is also directed to compositions containing the antibody-drug conjugates, and to methods of treatment using them.
    Type: Application
    Filed: September 26, 2006
    Publication date: November 13, 2008
    Applicant: Medarex, Inc.
    Inventors: Sharon Elaine Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Kilian Horgan, Bilal Sufi, Haichun Huang, David John King, Chin Pan, Josephine M. Cardarelli
  • Therapeutic human anti-IL1-R1 monoclonal antibody
    Patent number: 7438910
    Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: October 21, 2008
    Assignees: Amgen Inc., Medarex, Inc.
    Inventors: Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
  • Irta-4 Antibodies and Their Uses
    Publication number: 20080253962
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-4 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-4, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.
    Type: Application
    Filed: September 19, 2005
    Publication date: October 16, 2008
    Applicant: Medarex, Inc
    Inventors: Mohan Srinivasan, Josephine M. Cardarelli, Haichun Huang